Former InterMune Inc. CEO Scott Harkonen was fined $20,000 and sentenced to six months of home confinement in connection to a misleading 2002 company press release about the drug Actimmune.
Harkonen was convicted of wire fraud in September 2009 after Brisbane-based InterMune distributed an Aug. 28, 2002, press release that claimed that Actimmune in a Phase III trial reduced deaths by 70 percent in patients with mild to moderate idiopathic pulmonary fibrosis.
No comments:
Post a Comment